3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
3
Radiation Injuries
1
Prostatic Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Hepatitis
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Chemical and Drug Induced Liver Injury
1
Brain Injuries
1
Bone Cysts
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Mycophenolic Acid
2
vedolizumab
1
Ursodeoxycholic Acid
1
Steroids
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hepatitis
×
Steroids
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled